SYDNEY, Australia,29 November 2018: Award-winning medical device developer Atomo Diagnostics today announced that its Atomo HIV Self Test has been approved for sale in Australia by the Therapeutic Goods Administration (TGA).  It is the first and only diagnostic self-test for HIV to have received approval from Australia’s national regulator.   HIV self‑testing is the process whereby...

Today, Atomo Diagnostics announced that its Atomo HIV Self Test has been approved for sale in Australia by the Therapeutic Goods Administration (TGA).  It is the first and only diagnostic self-test for HIV to have received approval from Australia’s national regulator. Addressing the media following the announcement, Founder and CEO of Atomo Diagnostics,...

Today, Atomo Diagnostics was announced as a strategic partner to Mylan N.V. as part of the global pharmaceutical company's plans to commercialize CE-Marked in vitro HIV rapid diagnostic tests for self-testing in low- and middle-income countries. The self-tests, which use the innovative AtomoRapid platform, will allow individuals to confidently screen themselves...

HERTFORDSHIRE, England, PITTSBURGH and SYDNEY, September 24, 2018 – Global pharmaceutical company Mylan N.V.(NASDAQ: MYL) and medical device company Atomo Diagnostics today announced a strategic partnership to commercialize CE-Marked in vitro HIV rapid diagnostic tests for self-testing in low- and middle-income countries. The tests will allow...

From its impressive and newly expanded manufacturing plant close to the beautiful village of Guipry in northwest France, NG Biotech is rapidly scaling-up production to meet growing demand for its innovative products. The village setting is in stark contrast to the cutting-edge nature of NG...

Sydney, Australia and Woodstock, England – 05 June 2018 | Atomo Diagnostics and Owen Mumford Ltd have today announced a strategic partnership for commercialisation of innovative HIV rapid tests in European markets Owen Mumford acquires exclusive rights to Atomo’s HIV rapid tests for commercialisation under...

RPS Diagnostics partners with Atomo Diagnostics to develop next generation FebriDx blood tests for antibiotic stewardship in the outpatient setting Sarasota, Florida and Sydney, Australia (February 20, 2018) – United States biotechnology company, RPS Diagnostics (RPS®), and Australian medical device company, Atomo Diagnostics, announced today that...

Atomo Diagnostics is delighted to announce it's commercial and development partnership with US biotechnology company, RPS Diagnostics. In a joint Press Announcement, the companies have shared plans to create next generation FebriDx® tests that are anticipated to transform the diagnosis of febrile acute respiratory infections (ARI) at...

Sydney, Australia and Seoul, South Korea – 23 January 2018 | Atomo Diagnostics and Access Bio Inc. today announce a strategic partnership to leverage the respective strengths of both innovative rapid diagnostic test (RDT) companies to expand point of care HIV testing in global markets. ...

Sydney, Australia, 7 December 2017 | Atomo Diagnostics, the world leader in integrated point-of-care rapid diagnostic devices, announced today that its Atomo HIV Self Test has been confirmed as eligible for procurement by organisations entitled to access Global Fund and Unitaid resources. Atomo HIV Self...

Atomo Diagnostics' CEO John Kelly announced today that the Atomo HIV Self Test has been granted CE Marking by a European Union Notified Body. The company is now actively engaging with commercialisation and distribution partners to make the test widely available in European and other global markets during 2018...

SYDNEY, AUSTRALIA, October 10, 2017 – Atomo Diagnostics, a world leader in innovative point-of-care, rapid diagnostic devices, announced today that its Atomo HIV Self Test has been granted CE Marking by a European Union Notified Body. Atomo HIV Self Test granted CE Mark; will facilitate...

Sydney, Australia, May 30, 2017| Multi-award winning medical device innovator Atomo Diagnostics today announced its pioneering HIV self test product has been approved for sale in Kenya. Following successful product evaluations and in-field studies conducted in Kenya by investigators from the Kenya Medical Research Institute (KEMRI), Nairobi, Atomo...

Delighted to welcome new investors for 2017, earlier this month Atomo Diagnostics announced backing from Grand Challenges Canada (GCC). Investment from the Canadian Government-funded agency totalling US$1 million (A$1.31 million, C$1.32 million), in recognition of a ‘bold idea with big impact in global health’, will help...

SYDNEY, Australia, 1 February  2017: Medical device innovator Atomo Diagnostics today announced it had received US$1 million (A$1.31 million, C$1.32 million) in financing from Grand Challenges Canada to support its continued business operations. Funded by the Government of Canada, Grand Challenges Canada is dedicated to supporting Bold...

Guipry, France and Sydney, Australia, 8 November 2016 - French biotechnology company, NG Biotech, and Australian medical device innovator, Atomo Diagnostics, announced today that they have developed the world’s first fully-integrated blood-based rapid test for detection of hCG levels in pregnancy. The new product, NG-Test®...

Written by John Kelly, CEO at Atomo Diagnostics Since its formation in 2010, Atomo has been making waves in the diagnostics technology space with  award-winning products. The company is also recognised by key global health partners for  supporting early diagnosis of HIV, as well as its...

In the past 12 months Atomo has secured grant funding to commercialise various tests using its technology, including a grant from the NSW Medical Devices Fund for a digital HIV Self-Test and a grant from the Australian Commonwealth for a range of tropical fever tests. Today...